



**Erasmus Mundus Joint Master Degree**  
**International Master of Science in Infectious Diseases and One Health (IDOH)**

**Consortium Agreement between the Consortium and Associate Partners**

The **Université de Tours (former Université François-Rabelais de Tours)**, France (hereinafter UT, former UFRT), represented by M. Philippe Vendrix, President, as the **Coordinating Institution** of the IDOH Consortium (International Master of Science in Infectious Diseases and One Health) ("UT");

**Universitat Autònoma de Barcelona**, Spain (hereinafter UAB), represented by Pr Margarita Arboix Arzo, Rector ("UAB"); and

The **University Court of the University of Edinburgh**, UK (hereinafter UoE), represented by Professor David Argyle ("UoE")

(UT, UAB and UoE each being recognised partner institutions of the IDOH Consortium and being referred to collectively as the "**Consortium**" and individually as a "Partner")

and

- The Institut National de la Recherche Agronomique (INRA - France), represented by Catherine BEAUMONT, President of INRA Research Centre Val de Loire
- The Fédération de Recherche en Infectiologie (FéRI- France), represented by Denys BRAND, Director
- The Institut de Recerca I Tecnologia agroalimentaries (IRTA-CReSA, Spain), represented by Fernando RODRÍGUEZ, Director
- The Centre Pasteur du Cameroun (CPC, Cameroon), represented by Elisabeth CARNIEL, Director
- The International Livestock Research Institute (ILRI, Kenya) represented by Wellington Ekaya, Head of Capacity Development
- The Institute of Biochemistry (Romania), represented by Stefana PETRESCU, Director
- The Institut de Investigació en ciències de la Salut Germans Trias (IGTP, Spain), represented by Manel PUIG DOMINO, Director
- ~~The fundacio privada institut de recerca de l'Hospital de la Santa (IR-HSCSP, Spain), represented by Jaime KULISEVSKY BOJARSKI, Director~~
- The fundacio privada institut de recerca de la SIDA-CAIXA (IRSI-CAIXA, Spain), represented by Bonaventura CLOTET I SALA, Director
- The fundacio Hospital Universitari Vall D'Hebron (VHIR, Spain), represented by Joan X COMELLA CARNICE, Director
- The Institut National de Santé Publique de Guinée (INSP, Guinée Conakry), represented by Lamine KOIVOGUI, Director
- The Chiang Mai University (CMU, Thailand), represented by Wasna SIRIRUNGSI, Dean of the Faculty of Associated Medical Sciences
- The Universidad Nacional de la Plata (UNLP, Argentina), represented by Claudio BARBEITO, Dean of the Faculty of Veterinary Sciences,
- The Freie Universitaet Berlin (FUB), represented by Jurgen ZENTEK, Director of the Faculty of Veterinary Medicine
- The Royal Institution for the Advancement of Learning, McGill University (McGill University, Canada), represented by Josephine NALBANTOGLU, Dean



- The Ecole Nationale Vétérinaire, Agroalimentaire et de l'Alimentation (ONIRIS, France), represented by Dominique BUZONI-GATEL, Director
  - The Ross University School of Veterinary Medicine, (RUSVM, St Kitts and Nevis), represented by Dr. Sean Callanan, Dean of RUSVM
  - SRUC, Scotland's Rural College (SRUC, UK), represented by Mark Hocart, Manager of Postgraduate Studies,
  - The Universidad de Concepcion (Chile), represented by Patricio Hernan ROJAS CASTANEDA, Director of the Faculty of Veterinary Sciences,
  - The Universidade Federal de Minas Gerais (UFMG, Brazil), represented by Renato DE LIMA SANTOS, Dean of the Faculty of Veterinary Sciences,
  - ~~BioMerieux SA (France), represented by Alain PLUQUET, VP R&D Innovation~~
  - Boehringer Ingelheim VRC GmbH & Co. KG (Germany), represented by Stephan DOLLE and Jörg MEIL, Members of the BIVRC Board of Managing Directors
  - Laboratorios Calier SA (Spain), represented by Joaquim TARES, business developer director
  - CEVA Santé Animale, represented by Marc PRIKAZSKY, Director
  - CIELivestock (CIEL, UK), represented by Lyndsay CHAPMAN, CEO
  - ID Vet SARL (IDVet, France), represented by Philippe POURQUIER, Director
  - ~~LFB biotechnologies (LFB, France), represented by Sami CHTOUROU, Director Innovation~~
  - MixScience (France), represented by Jean Pierre PAILLOT, Director
  - ~~Lesaffre (Phileo Lesaffre, France), represented by Frédérique CLUZEL, General Manager~~
  - ~~Sanofi-Aventis (France), represented by Laurent FRAISSE, Head of the Infectious Diseases Department~~
  - Virbac SA (France), represented by Jean-Pascal MARC, Director Product Innovation
  - ~~Vitamfero (France), represented by Pascal BRETON, General Manager~~
  - Zoetis (Spain), represented by Alicia URNIZA, VRMD director
  - Ascil Biopharm (Spain), represented by Roland CHERIF-CHEIKH, Director
  - Etablissement Français du Sang (EFS - France), represented by François TOUJAS, President and
- (each individually being referred to as an “Associate Partner” and collectively as the “Associate Partners”)

HAVE EACH AGREED to the following terms and conditions, including those in the annexes, which form an integral part of this Consortium Agreement. They confirm their commitment and therefore reaffirm the advantage of joined forces in the creation, dissemination and application of knowledge on the International Master of Science in Infectious Diseases and One Health Erasmus Mundus Joint Master Degree (“EMJMD”) programme (project number 574319-EPP-1-2016-1-FR-EPPKA1-JMD-MOB) (the “IDOH programme”).

#### **Article 1 – Objective of the present Consortium Agreement**

On the basis of the present Consortium Agreement, the Consortium and the Associate Partners shall together contribute to the successful delivery of the IDOH Programme and the achievement of the requirements of the Grant Agreement (Grant agreement number: 2016-2071/001-001 in Annex 1) (the “Grant Agreement”).

#### **Article 2 – Entry into force and duration**

§1. The IDOH Programme came into force on 5 September 2016 (the “Commencement Date”) for the preparatory year and three (3) biennial editions will be offered by the Consortium (2017-2019, 2018- 2020, 2019-2021).



§2. The present Consortium Agreement shall enter into force as of the Commencement Date (notwithstanding the date(s) of signature hereof). It shall be valid as long as the Grant Agreement (as hereinafter defined) is active. It shall be renewable and modifiable by mutual agreement of each Partner and each Associate Partner, and following any new proposal selected by the EACEA (Education, Audiovisual & Culture Executive Agency). All such changes and modifications shall be done in writing and shall be signed by the authorised representatives of each Partner and each Associate Partner.

§3. Should a Partner or Associate Partner want to leave the Consortium Agreement before the end of the Grant Agreement, this Partner or Associate Partner shall discuss this with the other Partners and Associate Partners and shall follow the rules stipulated in the Grant Agreement.

### **Article 3 – Scope and definitions**

§1. UT is the Coordinating Institution of the Consortium. The Consortium has agreed to organise the IDOH Programme, approved and funded by the EACEA of the Commission of the European Communities (CEC) under the Erasmus+ Framework programme and has entered into a separate consortium agreement, dated 12<sup>th</sup> and 16<sup>th</sup> May 2017, in order to document the way in which each Partner has agreed to work together to deliver the IDOH Programme. A copy of the consortium agreement entered into among the Consortium is attached hereto as Annex 4.

§2. The IDOH programme will also involve the Associate Partners, who come from a range backgrounds (including academic, industrial and institutional) and who may be involved in the preparation, implementation and evaluation of the IDOH programme notably through the provision of guest lectures and internship opportunities.

§3. The activities to be carried out by the Partners and the Associate Partners are fully described in the Proposal (Annex 2). Each Partner and Associate Partner has approved its relative contribution to the realisation of the described activities in compliance with the Erasmus+ EMJMD programme rules and policies. Any divergence from this Proposal must be approved by all the Partners and Associate Partners and, if necessary, must be validated by the EACEA.

§4. All the responsibilities related to the management of the grant allocated to the Consortium by the EACEA are formalised through the Grant Agreement.

### **Article 4 – Responsibilities of the Coordinator**

§1. The Coordinator will be an individual that is nominated by UT as its representative and shall be made known to the other Partners and Associate Partners. The Coordinator shall organise the collaboration between each Partner and Associate Partner in compliance with the Proposal (Annex 2). He is the link between the EACEA and each Partner and Associate Partner and shall see to the effective application of the Proposal.

§2. UT will provide the EACEA with all the required reports on the IDOH Programme evolution and its financial management, in accordance with the Grant Agreement (Annex 1).

§3. UT shall manage in particular the following activities:

- the overall coordination and management of the IDOH Programme, including the programme promotion and services to students,
- the financial management of the IDOH Programme:
- the distribution of funding among the Consortium



- the monthly payment of the EMJMD scholarship monies to EMJMD scholarship recipients (including the subsistence allowance and contribution to travel and installation) and the payment of travel costs and accommodation for the guest lecturers-scholars. The costs for the guest lecturers-scholars should have been approved by UT;
- the signature of Student Agreement on behalf of the Consortium;
- The maintenance of a record of all academic transcripts for students; and
- The issuing of the joint award upon successful completion of the IDOH Programme by a student.

#### **Article 5 – Responsibilities of the Partners and Associate Partners**

Each Partner and Associate Partner shall perform and complete its share of the IDOH Programme activities, as stated in the Proposal and, in the case of each Academic Partner, in its letter of intent (Annex 2) in accordance with the requirements set out in the Grant Agreement (Annex 1).

#### **Article 6 – Management of the IDOH Programme**

**§1.** The management of the IDOH Programme will be handled by a multi-level and shared responsibility organisation: a Coordination Office, a Steering Committee, a Selection Committee, an Internal Evaluation Committee, and an External Evaluation Committee. The responsibilities of these committees are explained below. In addition to the committees listed below, the Coordination Office may, if necessary, designate the creation of other specific boards in order to cover other identified needs that may arise.

**§2.** The **Coordination Office (CO)** is headed by UT, and includes members from each of the Partners. It is responsible for managing and running the IDOH Programme professionally with appropriate human resources, equipment, and infrastructure. In particular, it will be responsible for the following:

- Coordination and daily running of the IDOH Programme
- Providing input into the development of a public web site ([www.infectious-diseases-one-health.eu](http://www.infectious-diseases-one-health.eu)) and an e-application tool, as well as common documentation
- Coordination of the selection campaign and the Selection Committee (SelCo) meeting, i.e., coordinating the call for applications, providing assistance for the applicants, collecting the applications and coordinating the screening and selection of the applicants
- Implementing the Student Agreement for the selected students
- Implementing the student flow, in collaboration with each Partner
- Locally preparing for incoming students (including assistance for visa/residence permits, housing, etc.)
- Locally preparing for incoming guest lecturers-scholars
- Collation of Internship proposals submitted by Partners and Associate Partners, approval of the Internship proposals, communication of Internship proposals to students; administration of student Internship applications and general management of Internships (including provision of initial guidance to students and organisation of theses defence)
- Financial management and budget follow-up
- Preparation of progress and final reports
- Coordination of external communications and public relations (publicising the call for applications, enhancing visibility of the partnership, etc.)
- Preparation and coordination of the meetings of the Steering Committee and the Internal and External Evaluation Committees





§3. The **Steering Committee (StrCo)** is the decision-making body of the Consortium, which gathers the advice and recommendations of all the other committees. It is composed of a selection of all professors and researchers involved in the IDOH Programme and is the general assembly of all Partners and Associate Partners. It is headed by the UT, and involves at least one staff member from each Partner. In addition, representatives from certain Associate Partners and a student representative will be invited to this committee in an external advisory capacity. The role of the StrCo is to:

- Define and discuss the strategy of the Consortium
- Define and discuss the curriculum, its set-up and follow up, its quality evaluation, its sustainability
- Define and discuss the promotion policy and related needs (including the web site and any other means)
- Discuss and approve the IDOH Programme agenda and its progress
- Discuss and approve the pedagogical and scientific contents of the IDOH Programme
- Discuss and approve the financial budget and its follow-up
- Define and discuss CO actions in respect to its here-above responsibilities
- Appoint at least one member per Partner for the Selection Committee
- Propose corrective actions when necessary

StrCo members will also be responsible for implementing the IDOH Programme within their local structures, taking decisions linked to local procedures as needed. In particular, they will be responsible for:

- Participating in the local awareness and promotion of the IDOH programme
- Participating in the preparation and publication of the call for applications
- Following up the selection campaign and providing assistance when needed
- Giving feedback to the rest of the StrCo and the CO throughout the action
- In general, cooperating in a trustworthy manner with the StrCo members and remaining in close contact with the CO and partners through the collaborative platforms, e-mails, phone, post, etc.

The StrCo will meet at least once a year and possibly more often upon member request, especially for quality follow-up and corrective actions. Because the Consortium is quite small (three partners) decisions will be taken as much as possible by a consensus of the whole StrCo. In case of disagreement or deadlock situation, any dispute shall be amicably settled through discussion between the Partners' representatives and, if needed, with external consultation (with Associate Partners for example). At last, if needed, a vote procedure may be requested and decision based on the majority of the votes shall be taken, each Partner having one vote, irrespective of the number of representatives from that Partner. This overall procedure ensures the full commitment of each Partner in any decision and gives a way for solving disputes if any should occur.

§4. The **Selection Committee (SelCo)** is composed of one member per Partner or such other composition as may be agreed by the Partners. The SelCo will be headed by the UT and be responsible for each edition of the screening and ranking of all the applicants and the selection of EMJMD scholarship recipients. It will propose a list of eligible students (including a reserve list) and scholars for an EMJMD scholarship, and will pass the list on to the Coordinator – via the Steering Committee – for notification to the EACEA. It will meet at least once a year for the selection process.

§5. The **Internal Evaluation Committee (IntEvCo)** consists of two student representatives (one from each year of the IDOH programme (where applicable)), one representative of the CO, one representative of the StrCo, one representative of the SelCo (provided always that the IntEvCo will include one representative from each Partner), two representatives of the Associate Partners (one from a HEI and another from an industry Associated Partner) who shall be selected by the CO, and a representative of the UAB (as the Partner



responsible for the QA programme), who shall act as chairman of the IntEvCo. Each group/committee elects its representative(s), except the Associate Partner and student representatives, which are appointed by the CO. The IntEvCo is responsible for a continuous assessment of all processes in the IDOH programme, including academic evaluation, resources, services, etc. The IntEvCo meets at the end of every semester.

**§6. The External Evaluation Committee (ExtEvCo)** consists of three external experts to ensure independence in the evaluation, two former students (other than in the first two years of the IDOH Programme) and the representative of the UAB (as the Partner responsible for QA programme). Mainly chosen for their expertise and their national representation in the academic sector, research, institutional or industry, they will evaluate the quality of the IDOH programme, promote good practices and propose evolution if needed. They are invited to interview students and alumni from the programme for their evaluation. The members of the ExtEvCo will be appointed by the UAB in cooperation with the Coordination Office. A publicly accessible evaluation report will be published every two years. The ExtEvCo shall meet once per edition of the IDOH programme, e.g., during the workshop, to submit its report to the Internal Evaluation Committee. A specific amount of money has been put into the budget for paying the work realised by external evaluators. Each external member of the ExtEvCo shall sign a non-disclosure agreement with the Partners, which terms shall be not less stringent than those stipulated in this Consortium Agreement, no later than 30 calendar days after their appointment or before any confidential information will be exchanged, whichever date is earlier

**§7.** More details concerning the QA Programme are described in the Proposal (Annex 2). Further aspects of the programme management, like services for the students, performance monitoring and evaluation, and interaction with non-educational actors shall be carried out as detailed in the Proposal (Annex 2).

#### **Article 7 – Description of the IDOH programme**

**§1.** The IDOH Programme is a full-time, two-year (4 semesters, 120 ECTS) programme. Students will register at UT for the full two years and, thereafter, must follow the rules of UAB and UoE when undertaking parts of the IDOH Programme offered by them.

Enrolled students start out at the UT (30 ECTS) during their first semester, continue at UAB (30 ECTS) during their second semester and afterwards attend a Summer School organized by the Consortium. For their third semester, students move to the UoE. During the fourth semester, students carry out their Master thesis research project in a Partner or Associated Partner laboratory (the “Internship”). They conclude their studies by attending a Workshop organized by the Consortium where they will defend their thesis (30 ECTS). The tuition language for the all courses is English. Additional courses in French and Spanish are given for language acquisition (see Annex 3).

**§2.** The IDOH programme is designed to provide a comprehensive and detailed education in infectious disease-related topics. Its aim is to provide students with the knowledge and skills to understand every relevant aspect of infection and immunity, and to be aware of the interconnection between humans, animals, and their environment (One Health). The mobility focus of the IDOH programme will give students the experience and skill set to adapt to different cultural situations, which is a prerequisite for globally fighting emerging diseases. The students will be prepared to pursue a career in the public or private sector, for example, working for NGOs, in private Research & Development, or earning a PhD degree. For an overview over the integrated curriculum, see Annex 3. This shall be reviewed and revised by the Steering Committee on a yearly basis.



## **Article 8 - Internship organization**

At the beginning of the second semester of the first year of an intake (i.e in January 2018 for an intake starting in September 2017), each Partner or Associate Partner will be asked by UT for an internship offer (i.e for an internship carried out from January 2019 to July 2019 for the intake 2017-2019). The different offers will then be approved by the CO and forwarded to students. Each student is responsible for his/her applications to these offers. The selection process will be defined by the Partner or Associate Partner offering the internship, in a fair manner. The Partner or Associate Partner offering the internship shall submit details of such selection process to the CO on demand and the CO shall have the right to require reasonable amendments to such selection processes. Each student should choose his/her internship and be selected for an internship before the April 16th of this second semester. This early choice will allow time for approval and the completion of any visa procedures

An Internship agreement should be completed and signed by all the parties (student, welcoming institution, a CO representative (one from UT) and the Dean of the Faculty of Pharmacy (UT) since students are registered in UT for the 2 years.

## **Article 9 - Services for the students during Internships**

§1. The quality and variety of services for students shall correspond to the standards set out in the EMJMD guidelines.

§2. During each Internship, each student will be supported by a supervisor from one of the Partners (“Local Administrative Manager”), and, if being hosted by an Associate Partner, a supervisor from the hosting Associate Partner institution (“Supervisor”), who will provide advice or assistance to the students during his/her Internship.

§3. The Local Administrative Managers (where the hosting institution is a Partner) or Supervisor (where the hosting institution is an Associate Partner) shall engage themselves in helping students with student visa applications and finding appropriate student accommodation; however, notwithstanding this, primary responsibility for these matters will rest with the students.

## **Article 10 - Intellectual Property Rights**

§1. Each Partner and Associate Partner hereby grants to each of the other Partners and Associate Partners a non-exclusive, non-transferable, royalty-free licence to use their respective names and logos including trademarks, solely for the purpose of performing their obligations and exercising their rights under this Consortium Agreement and the Grant Agreement. Each use of the names and/or logos shall be in such form as agreed in advance and in writing with the Partner or Associate Partner in question.

§2. For the purposes of this Consortium Agreement the ownership and/or control of Foreground Intellectual Property (as hereinafter defined) shall apply as following:

- Foreground Intellectual Property that was created or developed by a student shall be owned by the given student.
- If Foreground Intellectual Property is generated by a Partner or Associate Partner employee, it shall be subject to the rules of the employing Partner or Associate Partner.
- When Foreground Intellectual Property is developed jointly between students and/or employees of



one or more Partners and/or Associate Partner or between employees of two or more Partners and/or Associate Partners, it shall be jointly owned by the relevant parties ("Joint Owners"). Each Joint Owner shall be permitted to use such jointly owned Foreground Intellectual Property for research and education purposes. In respect of any jointly owned Foreground Intellectual Property, the Joint Owners shall negotiate a joint invention agreement, which shall specify the rights each Joint Owner shall have in relation to revenue sharing, protection and exploitation of the jointly owned Foreground Intellectual Property (either themselves or through third parties) and shall provide for fair and equitable sharing of patent costs, income, and invention management responsibilities based on the relevant Joint Owner's respective contributions to the jointly owned Foreground Intellectual Property. Unless and until the terms of such agreement are agreed, except as expressly shown herein, no Joint Owner shall grant any third party any right or licence under the jointly owned Foreground Intellectual Property without first obtaining the prior written agreement of the other Joint Owners. Each Partner and Associate Partner undertakes to procure the necessary rights from their employees as may be required to give effect to this article.

§3. For the purposes of this article and this Agreement, the following definitions shall apply:

- "Background Intellectual Property" means all and any Intellectual Property created and developed prior to the Commencement Date or, if generated after the Commencement Date is generated out with the scope of the IDOH programme and is introduced to and/or used in the implementation of the IDOH programme;
- "Foreground Intellectual Property" means all and any Intellectual Property created and developed by a Partner, Associate Partner or by any Student in the course of the the IDOH Programme, including any Internships;
- "Intellectual Property" means copyright works, patents, discoveries, improvements, inventions, trademarks, designs, information, data, formulae, specifications, results of tests and field trials, diagrams, expertise, techniques, technology, know-how and other intellectual property of any nature whatsoever including applications and the right to apply for registration of any of the foregoing rights.

§4. Any Background Intellectual Property shall at all times remain the sole and exclusive property of the Partner or Associate Partner to whom that Background Intellectual Property belonged prior to the beginning date of this Consortium Agreement.

§5. Each Partner and Associate Partner shall promptly and fully notify the other Partners and Associate Partners of any actual, threatened or suspected infringement of the other Partner's or Associate Partner's Intellectual Property rights which comes to the first Partner's attention and of any claim by any third party coming to its attention that the marketing and/or offering of the IDOH Programme infringes any rights of any third party.

§6. If appropriate, a specific chapter in the Internship agreement could be added and define precisely the Intellectual Property Ownerships for any results generated during the internship/work placement. The paragraph 2 of the article 10 and specifically the ownership of the Foreground Intellectual Property by the student is not applicable if the partner or the Associate Partner is subject to a collective or internal agreement or if the Partner or the Associate Partner agree upon different terms in the Internship agreement. In this case, a specific chapter in the internship agreement will be added.





#### **Article 11 - Confidential information**

§1. All data and other documents and information which is, or which should reasonably be expected to be confidential in nature; any Background Intellectual Property and any Foreground Intellectual Property (“Confidential Information”) supplied by or on behalf of any Partner or Associate Partner (the disclosing party) to another Partner or Associate Partner (the receiving party) under this Consortium Agreement shall remain the property of the disclosing party and shall be treated as confidential by the receiving party during the performance of this Consortium Agreement and for an indefinite period thereafter.

§2. The receiving party shall not during the term of this Consortium Agreement or at any time thereafter use any Confidential Information other than in the performance of their obligations under this Consortium Agreement or disclose any Confidential Information to any third party.

§3. Without prejudice to the above, the receiving party's obligations under the preceding article shall nevertheless cease to apply in the following cases:

- when any Confidential Information becomes available to the public generally other than through a breach of this article
- when the receiving party can prove that the Confidential Information was already in the public domain at the time of the receipt from the disclosing party or was received without any obligation of confidentiality
- when the Confidential Information was lawfully received from a third party without restriction or any breach of any obligation of confidentiality
- when the receiving party is required to disclose any Confidential Information pursuant to a court, judicial or other lawful order
- when the disclosure of Confidential Information is required to enable the receiving party to comply with the information disclosure obligations required by national legislation.

§4. Each Partner and Associate Partner should use reasonable efforts to promptly advise the other Partner or Associate Partner in writing of any unauthorised disclosure or misuse of its Confidential Information after it becomes aware of this unauthorised disclosure or misuse.

§5. Each Partner and Associate Partner shall take measures to comply with and to bind its employees and sub-contractors to comply with the confidentiality obligations stipulated hereabove, which may be waived only by the prior written authorization of the concerned disclosing party.

§6. Each Partner and Associate Partner shall make each student aware of the provisions of this Consortium Agreement and arrange to put in place a separate confidentiality agreement with any students as may be required.

#### **Article 12 - Student complaints and Discipline**

Each Associate Partner hosting a student during an Internship will keep the Partners informed about any complaints by or about students, including allegations of harassment. If necessary, the relevant Associate Partner will endeavour to resolve such complaints or appeals through its respective appropriate internal procedures. If a student remains dissatisfied after the Associate Partner has dealt with a complaint, the student may, when appropriate, be heard by the Coordination Office.

Students will be subject to the disciplinary codes and regulations of the Partner or Associate Partner at which they are currently studying. In the event of allegations being made against a student in relation to an incident



in which more than one Partner and/or Associate Partner is involved, the relevant Partners and or Associate Partners shall consult the Coordination Office on the actions to be taken and the procedures that shall apply.

#### **Article 13 - Insurance**

UT is responsible for entering into an agreement on behalf of the Consortium with an insurance company that covers all students enrolled in the IDOH Programme and fulfils the requirements set up by the EACEA as set out in the Grant Agreement. Furthermore, UT is responsible for paying the insurance premiums on behalf of the Consortium, with such costs to be covered out of the coordination lump sum. The insurance should cover the entirety of the incurred risks of the student including those in a research laboratory (especially biological and chemical hazards) in the context of the IDOH Programme.

Each Partner or Associate Partner, welcoming a student during the Internship, is responsible for giving notice of all relevant safety rules to the student.

#### **Article 14 – Liability**

§1. Each Partner and Associate Partner shall be solely liable toward the other Partners and Associate Partners for loss, destruction, damage or injury resulting from its own actions in the execution of this Consortium Agreement. Notwithstanding the foregoing, a Partners' aggregate liability shall be limited to once the Partner's share of the total cost of the project, provided such damage was not caused by a wilful act or gross negligence.

§2. Each Partner and Associate Partner shall be fully responsible for the performance of any part of its share of the Consortium Agreement.

#### **Article 15 – Regulation**

§1. This Consortium Agreement shall in all respect be in compliance with the terms of the related Grant Agreement (Annex 1) and be governed by French law. The settlement of any difference or conflict arising from or in connection with this Consortium Agreement shall be attempted by an amicable effort from the Partners. Only the French courts are competent to decide on the disputes which remain unresolved.

The following appendixes are part of the present Consortium Agreement:

- Annex 1: Grant Agreement
- Annex 2: IDOH programme proposal (award criterion step 1 and 2 award step 2 additional grants)
- Annex 3: IDOH curriculum overview and module descriptions
- Annex 4: Tripartite Consortium agreement among the Consortium



**Signatures and Stamps**

Done in thirty-nine originals in English.

For the Université de Tours (UT),

Date, Stamp, and Signature of the legal representative, M. Philippe Vendrix, President



12 FEV. 2019

Le Président  
de l'Université de Tours,

  
**Philippe VENDRIX**



For Universitat Autònoma de Barcelona (UAB),

Date, Stamp, and Signature of the legal representative, Margarita Arboix Arzo, Rectora







For the University of Edinburgh (UoE),

Date, ~~Stamp~~, and Signature of the legal representative, Prof. David Argyle.

A handwritten signature in dark ink, appearing to read "David J. Argyle".

1 / 2 / 2018  
Edinburgh



For The Institut National de la Recherche Agronomique (INRA - France),  
Date, Stamp, and Signature of the legal representative, Catherine BEAUMONT, President of INRA Research  
Centre Val de Loire

16 JAN. 2018

Catherine Beaumont


16 JAN. 2018

INRA

Présidente du centre de Recherche Val de Loire  
Déléguée régionale pour la région Centre



- For The Fédération de Recherche en Infectiologie (FéRI- France),  
Date, Stamp, and Signature of the legal representative, Denys BRAND, Director

8 February 2018  




- For The Institut de Recerca I Tecnologia agroalimentaries (IRTA-CReSA, Spain),  
Date, Stamp, and Signature of the legal representative, Fernando RODRIGUEZ, Director

20 DIC. 2017

**IRTA**  
CReSA  
Campus de la UAB - 08193 Bellaterra (Barcelona) Spain

DRAFT




Co-funded by the  
Erasmus+ Programme  
of the European Union



INFECTIOUS DISEASES  
**ONE HEALTH**

- For The Centre Pasteur du Cameroun (CPC, Cameroon).

Date, Stamp, and Signature of the legal representative, Elisabeth CARNIEL, Director

31/01/2018  
  
*Elisabeth Carniel*  
Elisabeth Carniel  
Directeur Général  
Centre Pasteur du Cameroun



- For The International Livestock Research Institute (ILRI, Kenya)


Date, Stamp, and Signature of the legal representative, Jimmy Smith, Director General.

26<sup>th</sup> June 2018






- For The Institute of Biochemistry (Romania),  
Date, Stamp, and Signature of the legal representative, Stefana PETRESCU, Director



*Stefana Petrescu*



Co-funded by the  
Erasmus+ Programme  
of the European Union



- For The Institut de Investigacio en ciencies de la Salut Germans Trias (IGTP, Spain),  
Date, Stamp, and Signature of the legal representative, Manel PUIG DOMINO, Director

  
  
Institut de Recerca  
Germans Trias i Pujc

09 FEB. 2018





- For The fundacio privada institut de recerca de l'Hospital de la Santa (IR-HSCSP, Spain),  
Date, Stamp, and Signature of the legal representative Jaime KULISEVSKY BOJARSKI, Director

No longer participating to the programme



- The fundacio privada institut de recerca de la SIDA-CAIXA (IRSI-CAIXA, Spain),  
Date, Stamp, and Signature of the legal representative, Bonaventura CLOTET I SALA, Director

13 December 2017

**IrsiCaixa**

Institut de Recerca de la Sida

Hospital Universitari Germans Trias i Pujol  
Ctra. de Canyet s/n. 2a Planta Maternal  
08916 Badalona. Spain





- Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR, Spain),  
Date, Stamp, and Signature of the legal representative Joan X COMELLA CARNICE, Director

A handwritten signature in blue ink, consisting of a series of loops and a long horizontal stroke at the bottom.



- For The Institut National de Santé Publique de Guinée (INSP, Guinée Conakry),  
Date, Stamp, and Signature of the legal representative Lamine KOIVOGUI, Director

  
  
Conakry le 18/01/2018  
Professeur Lamine Koivogui  
Directeur Institut National  
Santé Publique (INSP)  
Guinée






- For The Chiang Mai University (CMU, Thailand).

Date, Stamp, and Signature of the legal representative Wasna SIRIRUNGSI, Dean of the Faculty of  
Associated Medical Sciences

*W. Sirirungsri*

(Wasna SIRIRUNGSI)

30 January 2018





- For The Universidad Nacional de la Plata (UNLP, Argentina),

Date, Stamp, and Signature of the legal representative Claudio BARBEITO, Dean of the Faculty of Veterinary Sciences,

April 3<sup>th</sup> 2018

  
Dr. CLAUDIO GUSTAVO BARBEITO  
DECANO  
Facultad de Ciencias Veterinarias  
Universidad Nacional de La Plata





- For The Freie Universitaet Berlin (FUB),

Date, Stamp, and Signature of the legal representative Jurgen ZENTEK, Director of the Faculty of Veterinary  
Medicine

24.01.2018





- For The Royal Institution for the Advancement of Learning. McGill University (McGill University, Canada), Date, Stamp, and Signature of the legal representative Josephine NALBANTOGLU, Dean

  
DEAN GRADUATE & POSTDOCTORAL STUDIES

JANUARY 15, 2018  
DATE



- For The Ecole Nationale Vétérinaire, Agroalimentaire et de l'Alimentation (ONIRIS, France),  
Date, Stamp, and Signature of the legal representative Dominique BUZONI-GATEL, Director





Co-funded by the  
Erasmus+ Programme  
of the European Union



- For The Ross University School of Veterinary Medicine, (RUSVM, St Kitts and Nevis),  
Date, Stamp, and Signature of the legal representative Dr. Sean Callanan, Dean of RUSVM

A handwritten signature in black ink, appearing to read "SC", followed by a horizontal line.

Jan 15, 2018

**ROSS UNIVERSITY  
SCHOOL OF VET MEDICINE**

Co-funded by the  
Erasmus+ Programme  
of the European Union



- For SRUC, Scotland's Rural College (SRUC, UK),  
Date, Stamp, and Signature of the legal representative Dr Michael L Smith, Head of Contracts Office,

15/1/2018

*M. L. Smith*



SRUC

West Mains Road  
Edinburgh  
EH9 3JG



- For The Universidad de Concepción (Chile),

Date, Stamp, and Signature of the legal representative **Patricio Hernan ROJAS CASTANEDA**, Director of the Faculty of Veterinary Sciences.

  
**Dr. Patricio Rojas Castañeda**

Dean

Faculty Veterinary Sciences



Chillán, enero 26 de 2018



- For The Universidade Federal de Minas Gerais (UFMG, Brazil),  
Date, Stamp, and Signature of the legal representative Renato DE LIMA SANTOS, Dean of the Faculty of  
Veterinary Sciences,

We are still waiting for the signature



- For BioMerieux SA (France),

Date, Stamp, and Signature of the legal representative Alain PLUQUET, VP R&D Innovation

No longer participating to the programme



- For Boehringer Ingelheim VRC GmbH & Co. KG (Germany),  
Date, Stamp, and Signature of the representatives Stephan DOLLE and Jörg MEIL, Members of the BIVRC  
Board of Managing Directors

ppa.

Stephan-Guenther Dolle

ppa.

Dr. Jörg Meil



- For Laboratorios Calier SA (Spain),

Date, Stamp, and Signature of Joaquim TARES, Business developer director

16 ENE. 2019  
LABORATORIOS CALIER, S. A.  
Barcelonès 26 (Pla del Ramassà)  
Tel 93 849 51 33 Fax 93 840 13 98  
08520 LES FRANQUESES DEL VALLÈS  
(Barcelona) ESPAÑA

Co-funded by the  
Erasmus+ Programme  
of the European Union



INFECTIOUS DISEASES  
**ONE HEALTH**

- For CEVA Santé Animale:

Date, Stamp, and Signature of the legal representative Marc PRIKAZSKY, Director

*de 02/05/2018*

**CEVA SANTÉ ANIMALE**  
10 avenue de la Ballastière - CS 30126  
33501 LIBOURNE CEDEX  
RCS : Libourne B 301 763 405  
Tel. +33 (0)5 57 55 40 40



Co-funded by the  
Erasmus+ Programme  
of the European Union



- CIELivestock (CIEL, UK).

Date, Stamp, and Signature of the legal representative ~~Sam HOSTE, Chief Operating Officer~~

L E Chapman  
29/1/18

Centre for Innovation Excellence in Livestock



Lyndsay Chapman  
CEO CIEL

York Science Park, IT Centre,  
Innovation Way, Heslington,  
York YO10 5NP UK

+44 (0)1904 567743

+44 (0)7780 957787

lyndsay.chapman@cIELivestock.co.uk

www.cIELivestock.co.uk



- For ID Vet SARL (IDVet, France),

Date, Stamp, and Signature of the legal representative Philippe POURQUIER, Director

16/04/2018

**ID VET SARL**  
310, Rue Louis Pasteur  
34790 Grabels - France  
Tél. : 04 67 41 49 33  
Fax : 04 67 45 36 95  
Siret : 478 123 219 00022  
TVA : FR 17 478 123 219



- For LFB biotechnologies (LFB, France),

Date, Stamp, and Signature of the legal representative Sami CHTOUROU, Director Innovation

No longer participating to the programme (but provides lecturers)



- For MixScience (France),

Date, Stamp, and Signature of the legal representative Jean Pierre PAILLOT, Director

  
**MIXSCIENCE**  
Centre d'Affaires Odysée - ZAC Cicé Blossac  
CS17228 - 35172 BRUZ Cedex  
Tél. : 02 99 52 59 00 - Fax : 02 99 52 59 04  
RCS Rennes 538 829 136

24.01.18



- For Lesaffre (Phileo Lesaffre, France),

Date, Stamp, and Signature of the legal representative Frédérique CLUZEL, General Manager

No longer participating to the programme



- For Sanofi Aventis (France),

Date, Stamp, and Signature of the legal representative Laurent FRAISSE, Head of the Infectious Diseases Department

No longer participating to the programme



- For Virbac SA (France),

Date, Stamp, and Signature of the legal representative Jean-Pascal MARC, Director Product Innovation

**VIRBAC S.A.**

à Directoire et conseil de Surveillance

1ère Avenue - 2065 m - L.I.D. 06516 CARROS

BP 27 - 06511 CARROS CEDEX

Tél. 04 92 08 73 00 - Fax 04 92 08 73 09

RC Grasse B 417 350 311

24/05/18



- For Vitamfero (France),

Date, Stamp, and Signature of the legal representative Pascal BRETON, General Manager

No longer participating to the programme (this company has closed)





- For Zoetis (Spain),

Date, Stamp, and Signature of the legal representative Alicia URNIZA, VRMD director

**zoetis**

January 25, 2018

Ctra. Camprodon, s/n  
Vail de Blanya - Girona



- For Ascil Biopharm (Spain), *ASCIL Proyectos S.L.*

Date, Stamp, and Signature of the legal representative Roland CHERIF-CHEIKH, Director



- 2 MAYO 2018



- Etablissement Français du Sang (EFS-France),

Date, Stamp, and Signature of the legal representative represented by François TOUJAS, President

**M. François TOUJAS**  
Président  
de l'Etablissement Français du Sang

